glp1versus

Foundayo vs Rybelsus

orforglipron (GLP-1 receptor agonist (oral small-molecule)) vs semaglutide (GLP-1 receptor agonist) — a complete side-by-side comparison.

Eli Lilly and CompanyNovo Nordisk

Foundayo weight loss

12.4%

Rybelsus weight loss

4.4%

Foundayo dosing

Once daily

Rybelsus dosing

Once daily

Reviewed by Dr. Elena Vance, DOLast reviewed 8 sources cited

Quick Summary

Foundayo (orforglipron) and Rybelsus (semaglutide) are both glp-1 receptor agonist (oral small-molecule)s. In clinical trials, Foundayo showed greater weight loss (12.4% vs 4.4%).

See the comparison table below for detailed side-by-side data.

Foundayo vs Rybelsus: Full Comparison

FeatureFoundayo(orforglipron)Rybelsus(semaglutide)
Active Ingredientorforglipronsemaglutide
Drug ClassGLP-1 receptor agonist (oral small-molecule)GLP-1 receptor agonist
ManufacturerEli Lilly and CompanyNovo Nordisk
FDA Approved2026-04-012019-09-20
Approved Indications
  • Chronic weight management in adults with obesity (BMI >=30 kg/m^2), or overweight (BMI >=27 kg/m^2) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
Routeoraloral
FrequencyOnce dailyOnce daily
Starting Dose3 mg once daily3 mg daily
Maintenance Dose12 mg or 36 mg once daily7 mg or 14 mg daily
Max Dose36 mg once daily14 mg daily
Weight Loss (%)12.4%4.4%
A1C ReductionN/A (not indicated for diabetes)1.4%
Key TrialATTAIN-1 (72 weeks)PIONEER 1 (26 weeks)
List PricePricing announced at U.S. launch (April 2026); confirm with LillyDirect$935-$1,029/month
With InsuranceFormulary coverage evolving; many commercial plans expected to require prior authorization$25-$150/month (varies by plan)
Savings CardEli Lilly savings program details emerging via LillyDirect$10/month (Novo Nordisk savings card, commercially insured)

Side Effects: Foundayo vs Rybelsus

Side EffectFoundayoRybelsus
Nausea21-27%11-20%
Diarrhea15-20%5-10%
Vomiting10-16%4-8%
Constipation8-14%3-5%
Indigestion/dyspepsia6-10%Not reported
Abdominal pain5-9%5-11%
Headache5-8%Not reported
Fatigue4-7%Not reported
Hair loss3-5%Not reported
Pancreatitis (rare)<0.5%<0.5%
Decreased appetiteNot reported3-9%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Foundayo vs OzempicRybelsus vs OzempicFoundayo vs WegovyRybelsus vs WegovyFoundayo vs MounjaroRybelsus vs MounjaroFoundayo vs ZepboundRybelsus vs Zepbound

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Foundayo FDA Drugs@FDA approval record — FDA
  2. Rybelsus FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. ATTAIN-1 clinical trial record — ClinicalTrials.gov
  2. PIONEER 1 clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Aroda VR et al. PIONEER 1: Oral Semaglutide Monotherapy vs Placebo in Type 2 Diabetes. Diabetes Care 2019;42:1724-1732 — Diabetes Care
  2. Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med 2019;381:841-851 — New England Journal of Medicine

Manufacturer Information

  1. Rybelsus patient and healthcare provider website — Novo Nordisk

Reference Entries

  1. Semaglutide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.